The Diagnostic and Immunotherapeutic Value of CD248 in Renal Cell Carcinoma

• DOI: 10.3389/fonc.2021.644612
• Publication Date: 2021-03-12T07:26:36Z
• Authors: Keying Zhang; Chao Xu; Shaojie Liu; Yao Jiang; Xiaolong Zhao; Shanjin Ma; Yu Li; Fa Yang; Yan Wang; Ping Meng; Changhong Shi; Donghui Han; Weihong Wen; Weijun Qin
• Keywords: Gene signature

Background: Renal cell carcinoma (RCC) is the most common malignancy in urinary system. Despite substantial improvements available treatment options, survival outcome of advanced RCC unsatisfactory. Identifying novel biomarkers to assist early diagnosis and screen patients who are sensitive immunotherapy would be beneficial. CD248 a promising candidate that deserves investigated. Methods: The Cancer Genome Atlas (TCGA) data set clinical specimens were adopted analyze expression between normal tumor tissues. Univariate multivariate Cox regression analyses employed identify independent prognostic factors construct CD248-based signature. correlation among present signature, tumor-infiltrating immune cells (TIICs), mutation burden (TMB), immunomodulatory molecules was evaluated. weighted gene co-expression network analysis (WGCNA), enrichment analysis, miRNA performed explore underlying mechanism progression RCC. Results: overexpression related poor prognosis, signature could precisely stratify with different outcomes regardless training or testing cohort. reflect immunosuppressive landscape (i.e., increased infiltration regulatory T upregulated checkpoints), accompanied by deteriorated clinicopathologic indexes. TMB immunostimulatory also risk score generated from co-expressed sets identified through WGCNA algorithm, several Gene Ontology (GO) terms Kyoto Encyclopedia Genes Genomes (KEGG) pathways significantly enriched. result CD248-correlated further emphasized importance Conclusion: valuable biomarker improve diagnostic therapeutic efficiency effect genes may provide insight for study, help reveal expressive regulation CD248.